The FDA has approved an immune checkpoint inhibitor in combination with chemotherapy to treat certain adult patients with endometrial cancer The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with...
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The U.S. Food and Drug Administration (FDA) has approved quizartinib (Vanflyta) for the treatment of patients...
New oral hormonal therapy offers alternative to injections for some women with metastatic disease.
The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients...
The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved talazoparib (Talzenna) in combination with the antiandrogen therapy enzalutamide...
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to glofitamab-gxbm (Columvi) for select patients with B-cell...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate cancer The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza), in combination with...
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for certain...
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq (Polivy), in combination with a rituximab product,...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and infection The U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for adult and pediatric...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More